

2.1.1.	Rosiglitazone	35
2.1.1.1.	Pharmacological and pharmacokinetic properties.....	35
2.1.1.2.	Physiochemical properties.....	36
2.1.1.3.	Formulations studied	37
2.1.2.	Diltiazem-HCl.....	38
2.1.2.1.	Pharmacological properties	38
2.1.2.2.	Physiochemical properties.....	39
2.1.2.3.	Formulations studied	40
2.1.3.	Isosorbide-5-mononitrate (5-ISMN)	41
2.1.3.1.	Pharmacological properties	41
2.1.3.2.	Physiochemical properties.....	42
2.1.3.3.	Formulations studied	43
2.1.3.4.	The Geomatrix [®] formulation principle.....	43
2.1.3.4.1.	Swelling layers	45
2.1.3.4.2.	Erodible layers	45
2.1.3.5.	Types of Geomatrix [®] sustained release systems	46
2.1.3.5.1.	Geomatrix [®] Zero order release system	46
2.1.3.5.2.	Geomatrix [®] Binary release system.....	46
2.1.3.5.3.	Geomatrix [®] Quick-Slow release system	47
2.1.3.5.4.	Geomatrix [®] Slow-Quick release system	47
2.1.3.5.5.	Geomatrix [®] Positioned release system	47
2.1.3.5.6.	Geomatrix [®] Accelerated release system	47
2.1.3.5.7.	Geomatrix [®] Delayed release system.....	48
2.1.3.5.8.	Geomatrix [®] Multiple pulse system	48
2.1.4.	Chemicals, laboratory supplies and equipment	48
2.1.5.	HPLC system used for sample analysis	51
2.2.	Methods	51
2.2.1.	Composition of <i>in vitro</i> dissolution media	51
2.2.1.1.	USP 26 dissolution media	52
2.2.1.1.1.	Deionized water.....	52
2.2.1.1.2.	0.05M phosphate buffer (USP 26)	52
2.2.1.1.3.	Simulating Gastric Fluid sine pepsin, pH 1.2 (SGF) _{sp}	52

2.2.1.2.	Biorelevant dissolution media	53
2.2.1.2.1.	Fasted State Simulating Gastric Fluid pH 1.8 (FaSSGF)...	53
2.2.1.2.2.	Fasted State Simulating Intestinal Fluid, pH 6.5 (FaSSIF)	53
2.2.1.2.3.	Fed State Simulating Intestinal Fluid, pH 5.0 (FeSSIF)	54
2.2.1.2.4.	Simulated Colonic Fluid, pH 5.8 (SCoF)	54
2.2.1.2.5.	Simulated Colonic Fluid ***, pH 5.8 (SCoF***).....	54
2.2.1.2.6.	Ensure plus® (Abbott, Wiesbaden, Germany) ¹	55
2.2.1.2.7.	pH- and bile-component gradient FaSSIF media.....	55
2.2.1.2.8.	pH- and bile-component gradient FeSSIF media.....	56
2.2.1.2.9.	Physicochemical properties of the dissolution media	57
2.2.2.	Solubility determination	57
2.2.2.1.	Rosiglitazone maleate	58
2.2.2.2.	Diltiazem hydrochloride	58
2.2.2.3.	5-ISMN	58
2.2.3.	Methods for <i>in vitro</i> dissolution testing	59
2.2.3.1.	USP 26 apparatus II (Paddle)	59
2.2.3.1.1.	Rosiglitazone maleate: Set-up for dissolution investigations with the USP apparatus II, Paddle	60
2.2.3.1.2.	Diltiazem hydrochloride: Set-up for dissolution investigations with the USP apparatus II, Paddle.	60
2.2.3.1.3.	5-ISMN: Set-up for dissolution investigations with the USP apparatus II, Paddle.	61
2.2.3.2.	USP 26 apparatus III (reciprocating cylinder, BioDis®)	61
2.2.3.2.1.	Rosiglitazone maleate: Set-up for dissolution investigations with the USP apparatus III, BioDis.	62
2.2.3.2.2.	Diltiazem hydrochloride: Set-up for dissolution investigations with the USP apparatus III, BioDis.	64
2.2.3.2.3.	5-ISMN: Set-up for dissolution investigations with the USP apparatus III, BioDis.	65
2.2.4.	HPLC analysis.....	66
2.2.4.1.	HPLC set-up for rosiglitazone maleate determination.....	66
2.2.4.2.	HPLC set-up for diltiazem hydrochloride determination	68
2.2.4.3.	HPLC set-up for 5-ISMN determination	69

2.2.5.	Model independent approaches for comparing dissolution profiles	70
2.2.6.	IVIVC calculations	73
2.2.6.1.	Rosiglitazone maleate	73
2.2.6.2.	Diltiazem HCl.....	77
2.2.6.3.	5-ISMN	81
2.2.7.	Statistical evaluation methods	86
3.	RESULTS AND DISCUSSION.....	87
3.1.	Rosiglitazone maleate	87
3.1.1.	Solubility determination.....	87
3.1.2.	In vitro dissolution tests	88
3.1.2.1.	Biorelevant dissolution tests: <i>Carbopol</i> [®] tablet formulation	89
3.1.2.1.1.	Influence of the variation of the hydrodynamics on the release of rosiglitazone in FaSSGF pH 1.8.....	89
3.1.2.1.2.	USP apparatus II (Paddle) investigations.....	90
3.1.2.1.3.	USP apparatus III (BioDis) investigations	91
3.1.2.1.4.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results.....	94
3.1.2.1.5.	In vitro- in vivo correlations (IVIVCs)	96
3.1.2.2.	Biorelevant dissolution tests: Gelucire capsule formulation..	101
3.1.2.2.1.	Influence of the variation of the hydrodynamics on the release of rosiglitazone in FaSSGF pH 1.8.....	101
3.1.2.2.2.	USP apparatus II (Paddle) investigations.....	102
3.1.2.2.3.	USP apparatus III (BioDis) investigations	103
3.1.2.2.4.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results.....	106
3.1.2.2.5.	In vitro- in vivo correlations (IVIVCs)	108
3.1.3.	Discussion of the results obtained with different rosiglitazone maleate formulations	113
3.2.	Diltiazem-HCl.....	115
3.2.1.	Solubility determination.....	115
3.2.2.	In vitro dissolution tests	115

3.2.2.1.	Diltahexal 180 mg retard (Hexal AG)	116
3.2.2.1.1.	USP apparatus II (Paddle) investigations	116
3.2.2.1.2.	USP apparatus III (BioDis) investigations	118
3.2.2.1.3.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results	119
3.2.2.1.4.	In vitro- in vivo correlations (IVIVCs).....	120
3.2.2.2.	Diltiuc 180 mg retard (Merck Dura)	124
3.2.2.2.1.	USP apparatus II (Paddle) investigations	124
3.2.2.2.2.	USP apparatus III (BioDis) investigations	125
3.2.2.2.3.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results	126
3.2.2.2.4.	In vitro- in vivo correlations (IVIVCs).....	127
3.2.2.3.	Diltiazem retard ratiopharm 180 mg (Ratiopharm).....	129
3.2.2.3.1.	USP apparatus II (Paddle) investigations	129
3.2.2.3.2.	USP apparatus III (BioDis) investigations	130
3.2.2.3.3.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results	131
3.2.2.3.4.	In vitro- in vivo correlations (IVIVCs).....	132
3.2.2.4.	Dilzicardin 180 mg retard (AZU Pharma)	134
3.2.2.4.1.	USP apparatus II (Paddle) investigations	134
3.2.2.4.2.	USP apparatus III (BioDis) investigations	135
3.2.2.4.3.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results	136
3.2.2.4.4.	In vitro- in vivo correlations (IVIVCs).....	137
3.2.2.5.	Dilacor XR 180 mg retard (Watson Pharma)	139
3.2.2.5.1.	USP apparatus II (Paddle) investigations	139
3.2.2.5.2.	USP apparatus III (BioDis) investigations	140
3.2.2.5.3.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results	141
3.2.2.5.4.	In vitro- in vivo correlations (IVIVCs).....	142
3.2.2.6.	Dilzem 180 uno (Gödecke/Pfizer)	143
3.2.2.6.1.	USP apparatus II (Paddle) investigations	143
3.2.2.6.2.	USP apparatus III (BioDis) investigations	144

3.2.2.6.3.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results.....	145
3.2.2.6.4.	In vitro- in vivo correlations (IVIVCs)	146
3.2.2.7.	Dilacor XR 240 mg (Skye Pharma).....	147
3.2.2.7.1.	USP apparatus II (Paddle) investigations.....	147
3.2.2.7.2.	USP apparatus III (BioDis) investigations	148
3.2.2.7.3.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results.....	149
3.2.2.7.4.	In vitro in vivo correlations (IVIVCs)	150
3.2.2.8.	Comparison of the release profiles of three once-daily dosing diltiazem HCl products	151
3.2.2.8.1.	Comparison of the release profiles of three once-daily diltiazem-HCl products obtained in the Paddle apparatus	151
3.2.2.8.2.	Comparison of the release profiles of three diltiazem HCl once-daily dosing products using the BioDis fasted state method.....	152
3.2.3.	Discussion of the results obtained with different diltiazem-HCl formulations	154
3.3.	Isosorbide-5-mononitrate (5-ISMN)	157
3.3.1.	Solubility determination.....	157
3.3.2.	In vitro dissolutions tests.....	157
3.3.2.1.	Formulation R6M12E2.....	159
3.3.2.1.1.	USP apparatus II (Paddle) investigations.....	159
3.3.2.1.2.	USP apparatus III (BioDis) investigations	160
3.3.2.1.3.	Additional USP apparatus III examinations in Ensure plus®	161
3.3.2.1.4.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results.....	162
3.3.2.1.5.	USP apparatus II (Paddle) investigations with elevated ionic strength	164
3.3.2.1.6.	In vitro- in vivo correlations (IVIVCs)	164
3.3.2.2.	Formulation R6M12E3.....	168
3.3.2.2.1.	USP apparatus II (Paddle) investigations.....	168
3.3.2.2.2.	USP apparatus III (BioDis) investigations	169

3.3.2.2.3.	Additional USP apparatus III (BioDis) examinations in Ensure plus®	171
3.3.2.2.4.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results	172
3.3.2.2.5.	USP apparatus II (Paddle) investigations with elevated ionic strength	174
3.3.2.2.6.	In vitro- in vivo correlations (IVIVCs).....	174
3.3.2.3.	Formulation S6H32E.....	178
3.3.2.3.1.	USP apparatus II (Paddle) investigations	178
3.3.2.3.2.	USP apparatus III (BioDis) investigations	180
3.3.2.3.3.	Additional USP apparatus III (BioDis) examinations in Ensure plus®	181
3.3.2.3.4.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results	182
3.3.2.3.5.	USP apparatus II investigations with elevated ionic strength..	184
3.3.2.3.6.	In vitro- in vivo correlations (IVIVCs).....	184
3.3.2.4.	Formulation R4K21F.....	188
3.3.2.4.1.	USP apparatus II (Paddle) investigations	188
3.3.2.4.2.	USP apparatus III (BioDis) investigations	189
3.3.2.4.3.	Additional USP apparatus III (BioDis) examinations in Ensure plus®	190
3.3.2.4.4.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results	191
3.3.2.4.5.	USP apparatus II (Paddle) investigations with elevated ionic strength	193
3.3.2.4.6.	In vitro- in vivo correlations (IVIVCs).....	193
3.3.2.5.	Formulation R4K22F.....	196
3.3.2.5.1.	USP apparatus II (Paddle) investigations	196
3.3.2.5.2.	USP apparatus III (BioDis) investigations	197
3.3.2.5.3.	Additional USP apparatus III (BioDis) examinations in Ensure plus®	198

3.3.2.5.4.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results.....	199
3.3.2.5.5.	USP apparatus II (Paddle) investigations with elevated ionic strength	201
3.3.2.5.6.	In vitro- in vivo correlations (IVIVCs)	201
3.3.2.6.	Formulation R4K23F	204
3.3.2.6.1.	USP apparatus II (Paddle) investigations.....	204
3.3.2.6.2.	USP apparatus III (BioDis) investigations	205
3.3.2.6.3.	Additional USP apparatus III (BioDis) examinations in Ensure plus®	206
3.3.2.6.4.	Comparison of the USP apparatus II (Paddle) and the USP apparatus III (BioDis) results.....	207
3.3.2.6.5.	USP apparatus II (Paddle) investigations with elevated ionic strength	209
3.3.2.6.6.	In vitro- in vivo correlations (IVIVCs)	209
3.3.3.	Discussion of the results obtained with different 5-ISMN formulations	211
4.	SUMMARY	215
5.	ZUSAMMENFASSUNG	223
6.	BIBLIOGRAPHY	235
7.	APPENDICES	249
7.1.	Rosiglitazone maleate data.....	249
7.2.	Diltiazem-HCl data	258
7.3.	5-ISMN data	267
7.4.	Additional data	291
8.	ABBREVIATIONS	293